Kazuhiro Kakimi

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
    Kazuhiro Kakimi
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Lung Cancer 65:1-8. 2009
  2. ncbi ?? T-cell immunotherapy for lung cancer
    Yukihiro Yoshida
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Surg Today 41:606-11. 2011
  3. ncbi B cells regulate antibody responses through the medullary remodeling of inflamed lymph nodes
    Jun Abe
    Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    Int Immunol 24:17-27. 2012
  4. ncbi Impact of culture medium on the expansion of T cells for immunotherapy
    Keisuke Sato
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    Cytotherapy 11:936-46. 2009
  5. ncbi A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells
    Jun Nakajima
    Department of Cardiothoracic Surgery, The University of Tokyo Graduate School of Medicine, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Eur J Cardiothorac Surg 37:1191-7. 2010
  6. ncbi Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration
    Makoto Kurachi
    Department of Molecular Preventive Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    J Exp Med 208:1605-20. 2011

Collaborators

  • Michio Tomura
  • Akiteru Goto
  • Shigenori Goto
  • Toru Kaneko
  • Shiki Takamura
  • Yukihiro Yoshida
  • Jun Abe
  • Makoto Kurachi
  • Jun Nakajima
  • Satoshi Ueha
  • Kouji Matsushima
  • Keisuke Sato
  • Yusuke Shono
  • Hiroyuki Yoneyama
  • Masashi Fukayama
  • Tatsuya Tsukui
  • Kei Sugihara
  • Junko Kurachi
  • Hiromi Wada
  • Fumiko Suenaga
  • Shinichi Takamoto
  • Tomohiro Murakawa
  • Takeshi Fukami
  • Shuichi Noji
  • Makoto Kondo
  • Akihiro Hosoi
  • Kazuko Sakuta
  • Miki Sugiura

Detail Information

Publications6

  1. ncbi Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
    Kazuhiro Kakimi
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Lung Cancer 65:1-8. 2009
    ....
  2. ncbi ?? T-cell immunotherapy for lung cancer
    Yukihiro Yoshida
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Surg Today 41:606-11. 2011
    ..This review focuses on the current status of ?? T-cell-based immunotherapy for lung cancer...
  3. ncbi B cells regulate antibody responses through the medullary remodeling of inflamed lymph nodes
    Jun Abe
    Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    Int Immunol 24:17-27. 2012
    ..We propose that non-cognate B cells mediate the expansion of the plasma cell niche in LN through medullary remodeling, thereby regulating the size of the LN plasma cell pool...
  4. ncbi Impact of culture medium on the expansion of T cells for immunotherapy
    Keisuke Sato
    Department of Immunotherapeutics Medinet, Graduate School of Medicine, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    Cytotherapy 11:936-46. 2009
    ..The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers of reactive lymphocytes for adoptive transfer...
  5. ncbi A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells
    Jun Nakajima
    Department of Cardiothoracic Surgery, The University of Tokyo Graduate School of Medicine, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Eur J Cardiothorac Surg 37:1191-7. 2010
    ..This pilot feasibility study evaluates the safety and potential anti-tumour effects of activated autologous gammadelta T cells administered intravenously to patients...
  6. ncbi Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration
    Makoto Kurachi
    Department of Molecular Preventive Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    J Exp Med 208:1605-20. 2011
    ....